These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 8371915

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes.
    Ziai N, Dolan JW, Kacere RD, Brubaker RF.
    Arch Ophthalmol; 1993 Oct; 111(10):1351-8. PubMed ID: 8216015
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study.
    Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH.
    Ophthalmology; 2008 May; 115(5):790-795.e4. PubMed ID: 18452763
    [Abstract] [Full Text] [Related]

  • 5. The influence of Latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical study.
    Dinslage S, Hueber A, Diestelhorst M, Krieglstein G.
    Graefes Arch Clin Exp Ophthalmol; 2004 Aug; 242(8):654-60. PubMed ID: 15241610
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure.
    Toris CB, Zhan G, Fan S, Dickerson JE, Landry TA, Bergamini MV, Camras CB.
    J Glaucoma; 2007 Mar; 16(2):189-95. PubMed ID: 17473728
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Potential mechanism for the additivity of pilocarpine and latanoprost.
    Toris CB, Zhan GL, Zhao J, Camras CB, Yablonski ME.
    Am J Ophthalmol; 2001 Jun; 131(6):722-8. PubMed ID: 11384567
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens.
    Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J.
    Ophthalmology; 1993 Sep; 100(9):1305-11. PubMed ID: 8371916
    [Abstract] [Full Text] [Related]

  • 14. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients.
    Toris CB, Camras CB, Yablonski ME.
    Am J Ophthalmol; 1999 Jul; 128(1):8-14. PubMed ID: 10482088
    [Abstract] [Full Text] [Related]

  • 15. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes.
    Serle JB, Podos SM, Kitazawa Y, Wang RF.
    Jpn J Ophthalmol; 1998 Jul; 42(2):95-100. PubMed ID: 9587840
    [Abstract] [Full Text] [Related]

  • 16. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study.
    Alm A, Villumsen J, Törnquist P, Mandahl A, Airaksinen J, Tuulonen A, Marsk A, Resul B, Stjernschantz J.
    Ophthalmology; 1993 Sep; 100(9):1312-6; discussion 1316-7. PubMed ID: 8371917
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.